Sunscreen Innovation Act
The AADA has issued a letter of support for H.R. 4250, the Sunscreen Innovation Act, which would expedite the FDA’s approval process for new sunscreen ingredients while maintaining strict safety standards. In particular, the AADA supports allowing the Nonprescription Drugs Advisory Committee (NDAC) to provide recommendations on sunscreen ingredients to the FDA. The AADA is also pleased to see a provision that would allow the Secretary of HHS to appoint members of other federal advisory committees — or outside consultants with substantive expertise regarding sunscreen active ingredients — to the NDAC when sunscreen ingredients are reviewed. The AADA is also pleased that the bill includes provisions that strengthen Congressional oversight by requiring reporting of FDA’s activities and progress in the review of sunscreen ingredients. Read the AADA’s letter of support.
Medical research funding
Research helps reduce the incidence and the death rate attributed to skin cancer, and decreases health care costs overall. The AADA is calling on Congress to end sequestration and increase medical research funding.
- Medical research funding and access to treatment background information.
- In July 2014, the AADA joined with the One Voice Against Cancer (OVAC) coalition for an advocacy day on Capitol Hill to educate members of Congress and the Senate about the importance of federal funding for cancer research and prevention programs. The group — which included 25 national and state organizations representing millions of health care providers, patients, survivors, public health professionals, scientists, caretakers, and their families — visited the offices of 131 key members of congress.
- The AADA signed on to a coalition letter with the American Association for Cancer Research and more than 100 other groups calling on House and Senate leaders to make cancer research and biomedical science a national priority by providing at least $32 billion for the NIH and $5.26 billion for the National Cancer Institute (NCI) in FY 2015. Read the coalition letter.
- Read the AADA letters to the House and Senate chairs and ranking members of the Appropriations Subcommittees on Labor, Health and Human Services, Education, and Related Agencies in April 2014.
- The AADA signed on to letters from the One Voice Against Cancer (OVAC) coalition requesting more medical research funding in FY15. Read the letters to the House and the Senate in April 2014.
Academy action on network adequacy and transparency pays off
After collaboration with the American Academy of Dermatology Association (AADA), Rep. Rosa DeLauro (D-Conn.) and Sens. Sherrod Brown (D-Ohio) and Richard Blumenthal (D-Conn.) have introduced the Medicare Advantage Participant Bill of Rights Act of 2014 (HR 4998/S 2552) that would enhance beneficiary and physician protections, and improve transparency in the Medicare Advantage (MA) networks. Specifically, beginning in plan year 2015, the bill ensures that provider networks cannot be changed mid-year by terminating physicians without cause, and that networks will be finalized before open enrollment begins. This legislation does not prevent networks from dropping physicians without cause altogether, however it discourages it. Read more about the legislation.
The AADA was the first national physician organization to issue letters of support for this legislation. Read the AADA's letters of support to Rep. DeLauro and Sens. Brown and Blumenthal.
Academy offers first-hand expertise on telemedicine to House Energy and Commerce Health Subcommittee
In response to a request for comment, the AADA sent a letter to the House Energy and Commerce Health Subcommittee offering insight on the use of technology to advance the nation’s health care system and improve patient care. The AADA showcased teledermatology programs, AccessDerm and Inpatient TeleDerm, as well as the opportunities and challenges facing teledermatology. Read the AADA's letter on telemedicine.
Congressional hearing on telemedicine
In an effort to examine how technology and telemedicine can advance efficiency, quality, and access to health care, the U.S. House Subcommittee on Health held a hearing on telemedicine on May 1, 2014. Carrie L. Kovarik, MD, FAAD, chair of the AAD Telemedicine Task Force submitted a written statement on behalf of the Academy for this hearing.
USPSTF research plan on skin cancer
The United States Preventative Services Task Force (USPSTF) issued its draft research plan on skin cancer. The AADA issued a letter to the USPSTF urging the Task Force to expand its skin cancer research settings to include dermatology visits and screening programs, and not just primary care sites of service. The AADA also urged the Task Force to expand the scope of the research plan on skin cancer to include adolescents and young adults. Read more AADA recommendations to the USPSTF.
Physician groups concerned compounding law will impact patient access to treatments
The AADA - along with several other physician groups - has expressed concerns to the FDA regarding the agency's implementation of the Drug Quality and Security Act as it relates to in-office use. Physicians have reported experiencing difficulty accessing both repackaged and compounded drugs without a prescription for in-office use. Physician groups are calling on the FDA to implement the law the way Congress intended which was to protect physician and patient access to compounded drug products. Read the letter.
Provision in Public Health Services Act could expand non-physician scope of practice, diminish network adequacy
The “Non-Discrimination in Health Care Providers” provision in the Public Health Service Act prevents group health plans and health insurance companies from discriminating against any health care provider who is acting within the scope of that provider’s license or certification under applicable State law.
However, in some cases, this provision has allowed health professionals to expand their scope of practice under state law. These efforts could impair patient quality of care, therefore, the AADA is urging CMS to interpret this provision in a way that supports state scope of practice laws and asks CMS to support congressional efforts to repeal this provision.
Additionally, the AADA expressed concerns that an interpretation of this provision — which would allow discrimination against providers in reimbursement rates based on broad “market considerations” — could further exacerbate the issue of narrowing networks. Insurers could interpret the provision as a means to exclude whole categories of providers which could impede patient access to dermatologic care.
Read the AADA’s letter to CMS.
H.R. 2914, the Promoting Integrity in Medicare Act of 2013, would limit patient access to in-office services that physicians provide under the physician self-referral or Stark law.
- Read a coalition letter opposing H.R. 2914.
- The AADA and several other physician groups have joined Rep. Phil Roe, MD, (R-Tenn.) in calling on Speaker of the House Rep. John Boehner (R-Ohio) and Rep. Nancy Pelosi (D-Calif.) to preserve physicians’ abilities to provide in-office ancillary services such as pathology. Read the letter from Rep. Roe, the AADA, and other physician groups.
- The AADA signed on to a coalition letter to all members of the Senate Health, Education, Labor and Pensions Committee and Finance Committees, and to all members of House Ways and Means and Energy and Commerce encouraging them to request that the Office of the Inspector General exempt pathology providers from the safe harbor rule. Read the coalition letter.
Physician workforce shortage
With a physician workforce shortage projected to reach130,600 physicians in 2025, the AADA and other specialty societies are calling on Congress to protect Medicare beneficiary access to health care services by preserving existing Medicare financing for Graduate Medical Education (GME). Medicare’s current cap on financial support for GME prevents teaching hospitals from expanding the number of training positions and often prevents new hospitals from establishing teaching programs. In a joint letter, the organizations stressed that Medicare GME cuts will threaten access to care for millions of current and future patients. Read the AADA letter.
Drug approvals, warnings, recalls and shortages
The Academy works with the FDA to stay abreast of the latest actions that affect patient safety and access to dermatologic drugs.
Physicians across the country have expressed concern regarding the ongoing shortage of vital drug products. Unfortunately, drug shortages are affecting every medical specialty, including anesthesia, oncology, emergency medicine and dermatology. The Academy continues to work with FDA officials to resolve drug shortage issues.